Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Invested Capital (2020 - 2025)

Historic Invested Capital for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $165.1 million.

  • SAB Biotherapeutics' Invested Capital rose 34732.42% to $165.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.1 million, marking a year-over-year increase of 34732.42%. This contributed to the annual value of $26.0 million for FY2024, which is 5467.74% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Invested Capital stood at $165.1 million for Q3 2025, which was up 34732.42% from $12.0 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Invested Capital ranged from a high of $165.1 million in Q3 2025 and a low of $12.0 million during Q2 2025
  • Moreover, its 5-year median value for Invested Capital was $36.9 million (2024), whereas its average is $41.3 million.
  • Examining YoY changes over the last 5 years, SAB Biotherapeutics' Invested Capital showed a top increase of 34732.42% in 2025 and a maximum decrease of 7394.56% in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Invested Capital (Quarter) stood at $42.5 million in 2021, then decreased by 18.02% to $34.8 million in 2022, then surged by 64.56% to $57.3 million in 2023, then crashed by 54.68% to $26.0 million in 2024, then skyrocketed by 535.65% to $165.1 million in 2025.
  • Its last three reported values are $165.1 million in Q3 2025, $12.0 million for Q2 2025, and $21.4 million during Q1 2025.